Association of Blood MCP-1 Levels with Risk of Obstructive Sleep Apnea : A Systematic Review and Meta-Analysis
Background and objective: Among the broad variety of chemokines, monocyte chemoattractant protein-1 (MCP-1) is considered to be one of the most important chemokines. Among others, MCP-1 activates monocytes and other immune cells highly involved in inflammation. In the present systematic review and meta-analysis, we evaluated the relationship between serum/plasma MCP-1 levels and the risk of obstructive sleep apnea (OSA) in adults as a disease related to inflammation. Materials and methods: Four databases were systematically investigated until 12 July 2022. We used the Review Manager 5.3 software (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark) to extract and calculate the standardized mean difference (SMD) and its 95% confidence interval (CI) of plasma/serum levels of MCP-1 between adults with and without OSA. Results: Eight articles including eleven studies in adults were entered into the meta-analysis. The serum/plasma MCP-1 levels in adults with OSA were higher than that in the controls (SMD = 0.81; p = 0.0007) and as well as for adults with severe OSA compared to those with mild and moderate OSA (SMD = 0.42; p < 0.0001). The subgroup analysis showed that ethnicity was an effective factor in the pooled analysis of blood MCP-1 levels in adults with OSA compared to the controls (Asians: (p < 0.0001), mixed ethnicity: (p = 0.04), and Caucasians: (p = 0.89)). The meta-regression showed increasing serum/plasma MCP-1 levels in adults with OSA versus the controls, publication year, age of controls, body mass index (BMI) of controls, and sample size reduced, and also BMI and the apnea−hypopnea index of adults with OSA increased. Conclusions: The meta-analysis showed that compared to the controls, serum/plasma levels of MCP-1 in adults with OSA were significantly more, as well as adults with severe OSA having more serum/plasma MCP-1 levels compared to the adults with mild to moderate OSA. Therefore, MCP-1 can be used as a diagnostic and therapeutic factor in adults with OSA.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:58 |
---|---|
Enthalten in: |
Medicina (Kaunas, Lithuania) - 58(2022), 9 vom: 13. Sept. |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Imani, Mohammad Moslem [VerfasserIn] |
---|
Links: |
---|
Themen: |
Blood |
---|
Anmerkungen: |
Date Completed 26.09.2022 Date Revised 08.03.2023 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.3390/medicina58091266 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM346603153 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM346603153 | ||
003 | DE-627 | ||
005 | 20231226031841.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.3390/medicina58091266 |2 doi | |
028 | 5 | 2 | |a pubmed24n1155.xml |
035 | |a (DE-627)NLM346603153 | ||
035 | |a (NLM)36143943 | ||
035 | |a (PII)1266 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Imani, Mohammad Moslem |e verfasserin |4 aut | |
245 | 1 | 0 | |a Association of Blood MCP-1 Levels with Risk of Obstructive Sleep Apnea |b A Systematic Review and Meta-Analysis |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 26.09.2022 | ||
500 | |a Date Revised 08.03.2023 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Background and objective: Among the broad variety of chemokines, monocyte chemoattractant protein-1 (MCP-1) is considered to be one of the most important chemokines. Among others, MCP-1 activates monocytes and other immune cells highly involved in inflammation. In the present systematic review and meta-analysis, we evaluated the relationship between serum/plasma MCP-1 levels and the risk of obstructive sleep apnea (OSA) in adults as a disease related to inflammation. Materials and methods: Four databases were systematically investigated until 12 July 2022. We used the Review Manager 5.3 software (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark) to extract and calculate the standardized mean difference (SMD) and its 95% confidence interval (CI) of plasma/serum levels of MCP-1 between adults with and without OSA. Results: Eight articles including eleven studies in adults were entered into the meta-analysis. The serum/plasma MCP-1 levels in adults with OSA were higher than that in the controls (SMD = 0.81; p = 0.0007) and as well as for adults with severe OSA compared to those with mild and moderate OSA (SMD = 0.42; p < 0.0001). The subgroup analysis showed that ethnicity was an effective factor in the pooled analysis of blood MCP-1 levels in adults with OSA compared to the controls (Asians: (p < 0.0001), mixed ethnicity: (p = 0.04), and Caucasians: (p = 0.89)). The meta-regression showed increasing serum/plasma MCP-1 levels in adults with OSA versus the controls, publication year, age of controls, body mass index (BMI) of controls, and sample size reduced, and also BMI and the apnea−hypopnea index of adults with OSA increased. Conclusions: The meta-analysis showed that compared to the controls, serum/plasma levels of MCP-1 in adults with OSA were significantly more, as well as adults with severe OSA having more serum/plasma MCP-1 levels compared to the adults with mild to moderate OSA. Therefore, MCP-1 can be used as a diagnostic and therapeutic factor in adults with OSA | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Meta-Analysis | |
650 | 4 | |a Review | |
650 | 4 | |a Systematic Review | |
650 | 4 | |a blood | |
650 | 4 | |a cytokine | |
650 | 4 | |a meta-analysis | |
650 | 4 | |a monocyte chemoattractant protein-1 | |
650 | 4 | |a obstructive sleep apnea | |
650 | 7 | |a Chemokine CCL2 |2 NLM | |
700 | 1 | |a Sadeghi, Masoud |e verfasserin |4 aut | |
700 | 1 | |a Mohammadi, Mehdi |e verfasserin |4 aut | |
700 | 1 | |a Brühl, Annette Beatrix |e verfasserin |4 aut | |
700 | 1 | |a Sadeghi-Bahmani, Dena |e verfasserin |4 aut | |
700 | 1 | |a Brand, Serge |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Medicina (Kaunas, Lithuania) |d 1998 |g 58(2022), 9 vom: 13. Sept. |w (DE-627)NLM093687583 |x 1648-9144 |7 nnns |
773 | 1 | 8 | |g volume:58 |g year:2022 |g number:9 |g day:13 |g month:09 |
856 | 4 | 0 | |u http://dx.doi.org/10.3390/medicina58091266 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 58 |j 2022 |e 9 |b 13 |c 09 |